Hassen Kared

Singapore, 138648, Singapore

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 38 publications

Interleukin-17-associated inflammation in non-responders and B-cell remodeling after daratumumab in refractory immune thrombocytopenia.

Interleukin-17-associated inflammation in non-responders and B-cell remodeling after daratumumab in refractory immune thrombocytopenia.

Journal: Haematologica

Published: April 09, 2026

Safety and efficacy of daratumumab in immune thrombocytopenia.

Safety and efficacy of daratumumab in immune thrombocytopenia.

Journal: Blood advances

Published: May 28, 2025

Deficient SARS-CoV-2 hybrid immunity during inflammatory bowel disease.

Deficient SARS-CoV-2 hybrid immunity during inflammatory bowel disease.

Journal: Clinical immunology (Orlando, Fla.)

Published: August 14, 2024

Humoral and cellular responses to a fifth bivalent SARS-CoV-2 vaccine dose in patients with immune-mediated inflammatory diseases on tumour necrosis factor inhibitors: a prospective cohort study.

Humoral and cellular responses to a fifth bivalent SARS-CoV-2 vaccine dose in patients with immune-mediated inflammatory diseases on tumour necrosis factor inhibitors: a prospective cohort study.

Journal: The Lancet regional health. Europe

Published: August 05, 2024

Safety of baricitinib in vaccinated patients with severe and critical COVID-19 sub study of the randomised Bari-SolidAct trial.

Safety of baricitinib in vaccinated patients with severe and critical COVID-19 sub study of the randomised Bari-SolidAct trial.

Journal: EBioMedicine

Published: July 17, 2024

SLAMF7 defines subsets of human effector CD8 T cells.

SLAMF7 defines subsets of human effector CD8 T cells.

Journal: Scientific reports

Published: July 08, 2024

Vaccine responses and hybrid immunity in people living with HIV after SARS-CoV-2 breakthrough infections.

Vaccine responses and hybrid immunity in people living with HIV after SARS-CoV-2 breakthrough infections.

Journal: NPJ vaccines

Published: February 26, 2024

T cell responses to repeated SARS-CoV-2 vaccination and breakthrough infections in patients on TNF inhibitor treatment: a prospective cohort study.

T cell responses to repeated SARS-CoV-2 vaccination and breakthrough infections in patients on TNF inhibitor treatment: a prospective cohort study.

Journal: EBioMedicine

Published: January 31, 2024

Corrigendum: Experimental validation of immunogenic SARS-CoV-2 T cell epitopes identified by artificial intelligence.

Corrigendum: Experimental validation of immunogenic SARS-CoV-2 T cell epitopes identified by artificial intelligence.

Journal: Frontiers in immunology

Published: January 26, 2024

Combination of oligo-fractionated irradiation with nivolumab can induce immune modulation in gastric cancer.

Combination of oligo-fractionated irradiation with nivolumab can induce immune modulation in gastric cancer.

Journal: Journal for immunotherapy of cancer

Published: January 16, 2024

Dynamics of SARS-CoV-2 immunity after vaccination and breakthrough infection in rituximab-treated rheumatoid arthritis patients: a prospective cohort study.

Dynamics of SARS-CoV-2 immunity after vaccination and breakthrough infection in rituximab-treated rheumatoid arthritis patients: a prospective cohort study.

Journal: Frontiers in immunology

Published: September 18, 2023

PeptiVAX: A new adaptable peptides-delivery platform for development of CTL-based, SARS-CoV-2 vaccines.

PeptiVAX: A new adaptable peptides-delivery platform for development of CTL-based, SARS-CoV-2 vaccines.

Journal: International journal of biological macromolecules

Published: August 01, 2023

Showing 1-12 of 38

Last Updated: 09/26/2026